Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.
How this was made
The 30-second read
Why it matters
The disclosed data provide the first detailed immunogenicity read‑out beyond tumor‑specific T‑cell responses, which could materially affect EVAX's valuation.
Market read
New trial data are a primary catalyst for EVAX, with potential spill‑over to the broader AI‑immunotherapy sector.
What to watch
Regulatory pathway uncertainties and the need for larger pivotal trials may limit near‑term upside.
Background
Evaxion A/S (NASDAQ: EVAX) is a clinical‑stage TechBio company developing AI‑designed cancer vaccines. The company announced that new immune data from its phase‑2 EVX‑01 trial will be presented at the Society for Immunotherapy of Cancer meeting in November.
Ticker impact
Evaxion will present new phase‑2 immune data for its personalized cancer vaccine EVX‑01 at the SITC 2026 Annual Meeting.
likely upward pressure as market prices in the new efficacy data.
Phase‑2 data are material for a clinical‑stage biotech; fresh immunogenicity results often trigger price rallies.
Market effects
strengthens the AI‑driven immunotherapy niche and may boost peer biotech valuations.
European biotech investors may see increased interest in AI‑based vaccine platforms.
adds credibility to AI‑immunology approaches, potentially influencing global biotech funding trends.
Counterpoint
If the data are not as robust as presented, the hype could reverse, leading to a sell‑off.
Key entities
- companyEvaxion A/S
Clinical‑stage biotech developing AI‑designed immunotherapies.
- companyMerck & Co., Inc.
Provider of pembrolizumab (Keytruda) used in combination with EVX‑01.
